Patents by Inventor Marc Mercken

Marc Mercken has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Monoclonal antibodies directed against the microtubule-associated protein tau, hybridomas secreting these antibodies, antigen recognition by these monoclonal antibodies and their applications
    Publication number: 20020001857
    Abstract: The invention relates to a monoclonal antibody which forms an immunological complex with an epitope of an antigen belonging to normal human tau protein as well as abnormally phosphorylated human tau protein, with said tau protein being liable to be obtained from a brain homogenate, itself isolated from human cerebral cortex. The monoclonal antibodies of the invention can be used to detect tau and abnormally phosphorylated tau in brain extracts and in unconcentrated cerebrospinal fluid.
    Type: Application
    Filed: February 21, 2001
    Publication date: January 3, 2002
    Applicant: N.V. Innogenetics S.A.
    Inventors: Marc Vandermeeren, Eugeen Vanmechelen, Marc Mercken, Andre Van De Voorde
  • Monoclonal antibodies directed against the microtubule-associated protein tau
    Publication number: 20010018191
    Abstract: A monoclonal antibody which forms an immunological complex with a phosphorylated epitope of an antigen belonging to human abnormally phosphorylated tau protein. The tau protein ca be obtained from a brain homogenate, itself isolated from the cerebral cortex of a patient having Alzheimer's disease.
    Type: Application
    Filed: December 11, 2000
    Publication date: August 30, 2001
    Applicant: N.V. Innogenetics S.A.
    Inventors: Marc Mercken, Eva-Maria Mandelkow, Marc Vandermeeren, Eugeen Vanmechelen, Van De Voorde Andre
  • Monoclonal antibodies directed against the microtubule-associated protein tau
    Patent number: 6238892
    Abstract: A monoclonal antibody which forms an immunological complex with a phosphorylated epitope of an antigen belonging to human abnormally phosphorylated tau protein. The tau protein ca be obtained from a brain homogenate, itself isolated from the cerebral cortex of a patient having Alzheimer's disease.
    Type: Grant
    Filed: March 15, 1996
    Date of Patent: May 29, 2001
    Assignee: N.V. Innogenetics S.A.
    Inventors: Marc Mercken, Eva-Maria Mandelkow, Marc Vandermeeren, Eugeen Vanmechelen, André Van De Voorde
  • Isolated human tau peptide epitope which specifically binds monoclonal antibody AT120.
    Patent number: 6232437
    Abstract: An isolated human tau peptide epitope which specifically binds monoclonal antibody AT120 consisting of the amino acid sequence selected from the group consisting of SEQ ID Nos. 2, 3, 4, 15, 16, 17, 18, 19 and 20.
    Type: Grant
    Filed: July 7, 1999
    Date of Patent: May 15, 2001
    Assignee: N.V. Innogenetics S.A.
    Inventors: Marc Vandermeeren, Eugeen Vanmechelen, Marc Mercken, André Van de Voorde
  • Isolated human tau peptide
    Patent number: 6010913
    Abstract: The invention deals with isolated human tau peptide epitopes of SEQ ID Nos: 1 to 4, 7 and 15 to 20 which have the capability of binding AT120 monoclonal antibody.
    Type: Grant
    Filed: January 19, 1995
    Date of Patent: January 4, 2000
    Assignee: N.V. Innogenetics S.A.
    Inventors: Marc Vandermeeren, Marc Mercken, Eugeen Vanmechelen, Andre Van De Voorde
  • Monoclonal antibodies directed against the microtubule-associated protein tau, hybridomas secreting these antibodies, antigen recognition by these monoclonal antibodies and their applications
    Patent number: 5861257
    Abstract: The invention relates to a monoclonal antibody which forms an immunological complex with an epitope of an antigen belonging to normal human tau protein as well as abnormally phosphorylated human tau protein, with said tau protein being liable to be obtained from a brain homogenate, itself isolated from human cerebral cortex. The monoclonal antibodies of the invention can be used to detect tau and abnormally phosphorylated tau in brain extracts and in unconcentrated cerebrospinal fluid.
    Type: Grant
    Filed: February 15, 1995
    Date of Patent: January 19, 1999
    Assignee: N.V. Innogenetics S.A.
    Inventors: Marc Vandermeeren, Marc Mercken, Eugeen Vanmechelen, Andre Van De Voorde
  • Monoclonal antibodies directed against the microtubule-associated protein tau, and hybridomas secreting these antibodies
    Patent number: 5843779
    Abstract: The invention relates to a monoclonal antibody AT 120 which forms an immunological complex with an epitope of an antigen belonging to normal human tau protein as well as abnormally phosphorylated human tau protein, with said tau protein being liable to be obtained from a brain homogenate, itself isolated from human cerebral cortex. The monoclonal antibodies of the invention can be used to detect tau and abnormally phosphorylated tau in brain extracts and in unconcentrated cerebrospinal fluid.
    Type: Grant
    Filed: January 19, 1995
    Date of Patent: December 1, 1998
    Assignee: N.V. Innogenetics S.A.
    Inventors: Marc Vandermeeren, Marc Mercken, Eugeen Vanmechelen, Andre Van De Voorde